Effectiveness of an Internet-Based Self-Management Educational Program for Patients With Anxiety Disorders in China: A Pilot Nonrandomized Controlled Trial.

J Psychosoc Nurs Ment Health ServMar 23, 2026 (epub)
Clinical ResearchPsychiatry

Ruyu Ge, Xinyu Cao, Xiaozhen Song et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot nonrandomized controlled trial assessed an 8-week WeChat-based self-management education program among outpatients with anxiety disorders in China. Participants received the program (n = 43) or usual control (n = 52), with outcomes measured at baseline and after the intervention. Compared with controls, the intervention group had significant improvements in self-management (F = 7.53, p = .007) and quality of life (F = 6.02, p = .016), and a significant reduction in anxiety symptoms (F = 5.44, p = .022).

Key findings

  • Self-management improved in the intervention group relative to controls (F = 7.53, p = .007).
  • Quality of life improved compared with controls (F = 6.02, p = .016).
  • Anxiety symptoms decreased relative to controls (F = 5.44, p = .022).

Why it matters

The findings suggest that a structured digital self-management program may support several relevant outcomes for people receiving outpatient care for anxiety disorders. Improvements in both symptoms and quality of life are clinically pertinent, while the pilot design means the results are preliminary and warrant confirmation before broader conclusions about effectiveness.

What to keep in mind

The study was a pilot nonrandomized controlled trial, so group allocation may have introduced bias and the findings require confirmation in larger randomized trials.

Source

Published in J Psychosoc Nurs Ment Health Serv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.